Biotechnology and Genetic Engineering Discipline, Life Science School, Khulna University, Khulna, Bangladesh.
Nutrition, Exercise Physiology, and Sarcopenia Laboratory, Jean Mayer USDA Human Nutrition Research Center, Tufts University, Boston, MA, USA.
J Biomol Struct Dyn. 2024 Jan-Feb;42(1):393-411. doi: 10.1080/07391102.2023.2192823. Epub 2023 Mar 27.
Advances in antiaging drug/lead discovery in animal models constitute a large body of literature on novel senotherapeutics and geroprotectives. However, with little direct evidence or mechanism of action in humans-these drugs are utilized as nutraceuticals or repurposed supplements without proper testing directions, appropriate biomarkers, or consistent models. In this study, we take previously identified drug candidates that have significant evidence of prolonging lifespan and promoting healthy aging in model organisms, and simulate them in human metabolic interactome networks. Screening for drug-likeness, toxicity, and KEGG network correlation scores, we generated a library of 285 safe and bioavailable compounds. We interrogated this library to present computational modeling-derived estimations of a tripartite interaction map of animal geroprotective compounds in the human molecular interactome extracted from longevity, senescence, and dietary restriction-associated genes. Our findings reflect previous studies in aging-associated metabolic disorders, and predict 25 best-connected drug interactors including Resveratrol, EGCG, Metformin, Trichostatin A, Caffeic Acid and Quercetin as direct modulators of lifespan and healthspan-associated pathways. We further clustered these compounds and the functionally enriched subnetworks therewith to identify longevity-exclusive, senescence-exclusive, pseudo-omniregulators and omniregulators within the set of interactome hub genes. Additionally, serum markers for drug-interactions, and interactions with potentially geroprotective gut microbial species distinguish the current study and present a holistic depiction of optimum gut microbial alteration by candidate drugs. These findings provide a systems level model of animal life-extending therapeutics in human systems, and act as precursors for expediting the ongoing global effort to find effective antiaging pharmacological interventions.Communicated by Ramaswamy H. Sarma.
在动物模型中,抗衰老药物/先导物的发现进展构成了大量关于新型衰老治疗和衰老保护的文献。然而,由于在人类中几乎没有直接证据或作用机制——这些药物被用作营养保健品或重新定位的补充剂,而没有适当的测试方向、适当的生物标志物或一致的模型。在这项研究中,我们选择了先前已被确定的药物候选物,这些候选物在模型生物中有显著延长寿命和促进健康衰老的证据,并在人类代谢相互作用网络中对其进行模拟。通过对药物相似性、毒性和 KEGG 网络相关性评分进行筛选,我们生成了一个包含 285 种安全且可生物利用的化合物的文库。我们对该文库进行了查询,以呈现从长寿、衰老和饮食限制相关基因中提取的人类分子相互作用网络中动物衰老保护化合物的三重相互作用图的计算建模衍生估计。我们的发现反映了与衰老相关的代谢紊乱的先前研究,并预测了 25 种最佳连接的药物相互作用剂,包括白藜芦醇、表没食子儿茶素没食子酸酯、二甲双胍、曲古抑菌素 A、咖啡酸和槲皮素,作为与寿命和健康寿命相关途径的直接调节剂。我们进一步对这些化合物及其功能丰富的子网络进行聚类,以在相互作用网络枢纽基因集中识别长寿特异性、衰老特异性、伪全调节剂和全调节剂。此外,血清标记物用于药物相互作用以及与潜在的衰老保护肠道微生物物种的相互作用,区分了当前研究并呈现了候选药物对最佳肠道微生物改变的整体描述。这些发现为人类系统中的动物延长寿命治疗提供了系统水平的模型,并为加速正在进行的寻找有效的抗衰老药理干预的全球努力提供了前提。由 Ramaswamy H. Sarma 传达。